ストックスクリーナーアプリを入手
219.51
1.14%
-2.53
プレマーケット:
217.56
-1.95
-0.89%
前日終値:
$222.04
開ける：
$221.38
24時間の取引高:
956.62K
Relative Volume:
0.87
時価総額：
$31.98B
収益：
$5.40B
当期純損益:
$1.49B
株価収益率:
21.70
EPS:
10.1168
ネットキャッシュフロー:
$1.78B
1週間 パフォーマンス:
-2.32%
1か月 パフォーマンス:
-3.71%
6か月 パフォーマンス:
-17.25%
1年 パフォーマンス:
+2.36%
1日の値動き範囲:
$216.68
$221.47
1週間の範囲:
$216.68
$230.03
52週間の値動き範囲:
$216.68
$293.81
Resmed Inc Stock (RMD) Company Profile
Compare RMD vs ISRG, BDX, MDLN, ALC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
219.51 | 32.23B | 5.40B | 1.49B | 1.78B | 10.12 |
ISRG
Intuitive Surgical Inc
|
478.82 | 160.28B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
154.85 | 44.57B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
46.23 | 38.56B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
75.86 | 37.93B | 10.40B | 980.00M | 1.61B | 1.9749 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | JP Morgan | Overweight |
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
ResMed (NYSE:RMD) Reaches New 52-Week LowWhat's Next? - MarketBeat
ResMed Inc stock hits 52-week low at 218.27 USD - Investing.com
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Resmed's Q3 Earnings on Deck: What's in Store for the Stock? - TradingView
ResMed Inc. $RMD Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Reduces Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) Projected to Post Earnings on Thursday - MarketBeat
Global Respiratory Care Devices Market to Grow at a Substantial Growth Rate of ~8% by 2034 | DelveInsight - GlobeNewswire Inc.
OVERSEA CHINESE BANKING Corp Ltd Sells 7,795 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Mirae Asset Global Investments Co. Ltd. Boosts Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc stock (US75102W1036): Is its sleep apnea dominance strong enough for long-term investor g - AD HOC NEWS
ResMed Inc. stock (US7611521078): Is its sleep apnea dominance strong enough for long-term investor - AD HOC NEWS
ResMed Inc. (RMD) stock price, news, quote and history - Yahoo Finance Singapore
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again - Yahoo Finance
ResMed Inc. stock (US7611521078): Is the U.S. sleep apnea market strong enough to unlock new upside? - AD HOC NEWS
ResMed Inc. (RMD) Investor Outlook: Unveiling a 28% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
RMD Stock Price, Quote & Chart | RESMED INC (NYSE:RMD) - ChartMill
JPMorgan Issues Overweight Rating for ResMed Amid Sleep Apnea Shift - HarianBasis.co
JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT - Insider Monkey
Mizuho Maintains ResMed Inc.Depositary Receipt (RSMDF) Outperform Recommendation - MSN
Lbp Am Sa Buys 18,142 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Should you continue to hold Resmed stock in your portfolio? - MSN
Should You Continue to Hold Resmed Stock in Your Portfolio? - TradingView
KBC Group NV Has $57.23 Million Position in ResMed Inc. $RMD - MarketBeat
Hendershot Investments Inc. Increases Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
INVESCO V.I. Health Care Fund's ResMed Inc(RMD) Holding History - GuruFocus
ResMed, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares? - The Motley Fool Australia
ResMed Inc. stock (US7611521078): Why does its sleep apnea dominance matter more now? - AD HOC NEWS
ResMed (NYSE:RMD) Now Covered by JPMorgan Chase & Co. - MarketBeat
Baird Adjusts Price Target on ResMed to $254 From $272, Maintains Neutral Rating - marketscreener.com
ResMed Inc. $RMD Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
ResMed Inc. stock (US7611521078): Is sleep apnea market growth strong enough to unlock new upside? - AD HOC NEWS
ResMed Inc. $RMD Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
RMD Analyst Rating Maintained at Outperform by Evercore ISI - Meyka
ResMed Inc (NYSE:RMD): A Durable Dividend Growth Stock for Passive Income - ChartMill
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Ord Minnett - The Globe and Mail
ResMed Inc. (RMD) Stock Analysis: Exploring a 29.56% Upside Potential with Robust Revenue Growth - DirectorsTalk Interviews
Wells Fargo Analyst Raises ResMed (RMD) Price Target to $270 | R - GuruFocus
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Trade Ideas — LSX:935168 - TradingView
ResMed Faces Shifting Market Signals in Healthcare Space - Kalkine Media
ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares - MarketBeat
Citigroup Issues Pessimistic Forecast for ResMed (NYSE:RMD) Stock Price - MarketBeat
Resmed CEO Farrell sells $1.12 million in stock - Investing.com
Resmed CEO Farrell sells $1.12 million in stock By Investing.com - Investing.com Australia
ResMed (RMD) CEO Farrell sells 4,991 shares after option exercise - Stock Titan
ResMed Insider Selling Raises Questions On Management Conviction And Valuation - Sahm
ResMed Inc. stock rises Wednesday, still underperforms market - MarketWatch
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
0.75%
12.86%
大文字化:
|
ボリューム (24 時間):